Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of regulatory T cells in cancer immunology
Theresa L. Whiteside
ImmunoTargets and Therapy (2015), pp. 159-159
Open Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Inflammation and tumor progression: signaling pathways and targeted intervention
Huakan Zhao, Lei Wu, Guifang Yan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1599
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
Belal Chaudhary, Eyad Elkord
Vaccines (2016) Vol. 4, Iss. 3, pp. 28-28
Open Access | Times Cited: 435
Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma
Jason Behary, Nadia Amorim, Xiaotao Jiang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 309
Emerging Opportunities and Challenges in Cancer Immunotherapy
Theresa L. Whiteside, Sandra Demaria, María E. Rodríguez-Ruiz, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 8, pp. 1845-1855
Open Access | Times Cited: 280
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
Danielle Benedict Sacdalan, Josephine Anne Lucero, Dennis L. Sacdalan
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 955-965
Open Access | Times Cited: 276
Regulatory T cells in the treatment of disease
Amir Sharabi, Maria Tsokos, Ying Ding, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 11, pp. 823-844
Open Access | Times Cited: 263
Clinical development of targeted and immune based anti-cancer therapies
Nicole A. Seebacher, Alexandra E. Stacy, Georgia Porter, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 208
Targeting regulatory T cells in tumors
Chang Liu, Creg J. Workman, Dario A.A. Vignali
FEBS Journal (2016) Vol. 283, Iss. 14, pp. 2731-2748
Open Access | Times Cited: 205
The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach
Daniëlle Krijgsman, Marianne Hokland, Peter J.K. Kuppen
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 201
Mechanisms of immune evasion in bladder cancer
Paul L. Crispen, Sergei Kusmartsev
Cancer Immunology Immunotherapy (2019) Vol. 69, Iss. 1, pp. 3-14
Open Access | Times Cited: 167
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, et al.
Cancer Discovery (2018) Vol. 8, Iss. 10, pp. 1258-1269
Open Access | Times Cited: 154
FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity
Theresa L. Whiteside
Expert Opinion on Therapeutic Targets (2018) Vol. 22, Iss. 4, pp. 353-363
Open Access | Times Cited: 151
Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma
Axel Lechner, Hans Schlößer, Martin Thelen, et al.
OncoImmunology (2019) Vol. 8, Iss. 3, pp. 1535293-1535293
Open Access | Times Cited: 131
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
Etienne Foucher, Clément Ghigo, Salem Chouaı̈b, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 118
The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
Nanna Jørgensen, Gry Persson, Thomas Vauvert F. Hviid
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 112
Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment
Azharuddin Sajid Syed Khaja, Salman M. Toor, Haytham El Salhat, et al.
Oncotarget (2017) Vol. 8, Iss. 20, pp. 33159-33171
Open Access | Times Cited: 109
Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy
Panagiotis Balermpas, Daniel Martin, Ulrike Wieland, et al.
OncoImmunology (2017) Vol. 6, Iss. 3, pp. e1288331-e1288331
Open Access | Times Cited: 95
Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors
Xiulan Lai, Andrew Stiff, Megan Duggan, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 21, pp. 5534-5539
Open Access | Times Cited: 94
Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
Athanasios Κotsakis, Filippos Koinis, Afroditi Katsarou, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 90
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
Xiaoting Zhou, Yanghong Ni, Xiao Liang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 52
Magnesium alloys in tumor treatment: Current research status, challenges and future prospects
Yuchien Hsu, Yupu Lu, Siyi Wang, et al.
Journal of Magnesium and Alloys (2023) Vol. 11, Iss. 10, pp. 3399-3426
Open Access | Times Cited: 22
Targeting adenosine in cancer immunotherapy: a review of recent progress
Theresa L. Whiteside
Expert Review of Anticancer Therapy (2017) Vol. 17, Iss. 6, pp. 527-535
Open Access | Times Cited: 75
Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer
Yingjie Nie, Jiang He, Hidekazu Shirota, et al.
Science Signaling (2018) Vol. 11, Iss. 511
Open Access | Times Cited: 64
MicroRNA‐124‐3p suppresses PD‐L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling
Elmira Roshani Asl, Yousef Rasmi, Behzad Baradaran
Journal of Cellular Physiology (2021) Vol. 236, Iss. 10, pp. 7071-7087
Closed Access | Times Cited: 48
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies
Ehsan Gharib, Gilles A. Robichaud
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9463-9463
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top